COVID-19 mAb supplies could fall short of demand

Regeneron and Vir will soon start clinical trials of mAbs to treat and prevent COVID-19, but both companies are warning that manufacturing capacity constraints could limit access.

Speaking at the BIO International Convention, George Yancopoulos, co-founder, president and CEO of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), said trials of the company’s mAb cocktail will start in “a few days.” The trials will test the mAb cocktail as prophylaxis, and as treatments for early stage and hospitalized COVID-19 patients, he said. ...